1 Min Read
Jan 16 (Reuters) - Leap Therapeutics Inc:
* LEAP THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH TRX518 COMBINATION THERAPY IN ADVANCED SOLID TUMORS TRIAL Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.